http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Ginkgo Bioworks Provides Preliminary Unaudited 2022 Revenue Highlights and Business Review
-
Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immuno-oncology
-
Ginkgo Bioworks Expands Its R&D Facilities, Opens Bioworks7 to Conduct Mammalian Screening at Scale, Widening Capabilities for Biopharma Partners
-
Ginkgo Bioworks (DNA) and Esperovax Partner to Develop Circular RNA-based Therapeutics
-
Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics
-
Ginkgo Bioworks Announces Participation in the 41st Annual J.P. Morgan Healthcare Conference
-
Ginkgo Bioworks and the Ministry of Health of the Republic of Botswana Announce Plans to Develop and Implement New Biosecurity Capabilities in Botswana
-
Ginkgo Bioworks Launches Ginkgo Enzyme Services, Enabling Applications across Pharmaceuticals and Diagnostics, Food and Agriculture, and Beyond
-
Ginkgo Bioworks Provides Compensation Information Related to Recent Acquisitions
-
Ginkgo Bioworks Reports Third Quarter 2022 Financial Results
-
Ginkgo Bioworks Announces Date of Third Quarter 2022 Results Presentation
-
Ginkgo Bioworks Reports Second Quarter 2022 Financial Results
-
Ginkgo Bioworks and XpresCheck Receive Award to Expand CDC’s Traveler-Based SARS-CoV-2 Genomic Surveillance Program In U.S. Airports
-
Ginkgo Bioworks Announces Date of Second Quarter 2022 Results Presentation
-
EATV, the World's First Plant-based Innovation ETF, Makes History at The New York Stock Exchange (NYSE: EATV)
-
Ginkgo Bioworks Reports First Quarter 2022 Financial Results
-
Ginkgo Bioworks Announces Date of First Quarter 2022 Results Presentation
-
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results
-
Ginkgo Bioworks (DNA) and XpresCheck (XSPA) Reports Results of CDC COVID-19 Air Travel Biosecurity Program at International Airports
-
CDC, Concentric by Ginkgo and XpresCheck® Publish Results of CDC COVID-19 Air Travel Biosecurity Program at International Airports
-
Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2021 Results Presentation and Date for Annual Meeting of Shareholders
-
Concentric by Ginkgo and XpresCheck™ Confirm First North American Detections of Novel BA.3 Sublineage of Omicron Variant through CDC COVID-19 Air Travel Biosecurity Program
-
Concentric by Ginkgo Confirms Detection of Omicron Variant through COVID-19 Air Travel Biosecurity Collaboration with CDC and XpresCheck
-
XpresSpa Group Inc. (XSPA) and Ginkgo (DNA) Collaborates with CDC For Detection of the New Omicron Variant
-
XpresSpa Group and Ginkgo Bioworks Collaboration with the Centers for Disease Control and Prevention (CDC) COVID-19 Biosurveillance Program Expands to Include Detection of the New Omicron Variant
-
Ginkgo Bioworks Reports Third Quarter 2021 Results
-
Ginkgo Bioworks Announces Date of Third Quarter 2021 Results Presentation
-
Ginkgo Bioworks Previews Today's Annual Ferment Conference
-
Pre-Open Stock Movers 10/07: (CEI) (RKLB) (APP) Higher; (OSMT) (LW) (DNA) Lower (more...)
-
After-Hours Stock Movers 10/06: (CEI) (RKLB) (APP) Higher; (OSMT) (DNA) Lower (more...)
-
Cathie Wood's ARK Aggressively Adds More Ginkgo Bioworks (DNA), Sells More Tesla (TSLA)
-
Ginkgo Bioworks Provides First Half 2021 Update
-
Applied DNA Sciences (APDN) Reports Pact with TYME Technologies for Functional Invasive Circulating Tumor Cell Assay Services in Pancreatic Cancer Trial
-
Applied DNA Sciences Subsidiary LineaRx Signs Agreement with TYME Technologies for Functional Invasive Circulating Tumor Cell Assay Services in Pancreatic Cancer Trial
-
Applied DNA Sciences Reports 14 Development Customers for its Linear DNA Manufacturing Platform
-
Applied DNA’s SigNature® DNA Evidence Helps to Convict Over 131 Criminals to Date
-
Applied DNA and Eurofins BLC Sign Collaboration Agreement to Support Commercial Implementation of Leather Traceability System
-
Applied DNA Forms Wholly Owned Subsidiary, LineaRx, to Develop Large-Scale, PCR-Produced DNA for Biotherapeutics
-
Applied DNA Forms Wholly Owned Subsidiary, LineaRx, to Develop Large-Scale, PCR-Produced DNA for Biotherapeutics
-
Applied DNA Sciences (APDN) Secures 2-Yr Contract from U.S. Defense Logistics Agency
-
Applied DNA Executes New Two-Year Contract with the U.S. Defense Logistics Agency
-
Applied DNA Announces $1.65 Million Private Placement of Secured Convertible Notes
-
Applied DNA Presenting Linear DNA for Gene Therapy at Boston Immuno-Oncology Summit
-
Applied DNA Sciences Pens Deal with WestPoint Home for CertainT Program
-
Applied DNA and TheraCann International Conduct Successful Tagging and Testing Pilot of Legal Cannabis and Derivative-Products
-
Applied DNA’s SigNature® DNA Evidence Puts Father and Son Team Behind Bars
-
Applied DNA Awarded Multi-Year Contract to Develop Molecular Tracking Systems for Legal Cannabis Worldwide
-
Applied DNA Expands Internationally with New Central DNA Testing Laboratory in India
-
Applied DNA Introduces “GeoTyping” Beta Program Through February 2018 to Brands and Retailers Demanding Cotton Fiber Authenticity
-
SigNature® DNA Evidence by Applied DNA Used to Convict Criminal in Cash-in-Transit Robbery

